The labor dispute between Samsung Biologics’ union and management is escalating as talks over wages and bonuses remain ...
Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the first quarter of fiscal year 2026.
A court ruling has partly curbed Samsung Biologics labor union’s plan to stage an all-out strike, in a move seen as ...
Recorded Q2'25 consolidated revenue of KRW 1,289.9 billion Recorded Q2'25 consolidated operating profit of KRW 475.6 billion Solid momentum sustained through capacity ramp-up and stable project ...
INCHEON, South Korea, ROCKVILLE, Md. and LONDON , Dec. 21, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing ...
Samsung Biologics, the biopharmaceutical arm of Samsung Group, said on May 26 it had secured two contract manufacturing deals worth a combined 4.4 trillion won ($320 million) with European and Asian ...
The labor dispute at Samsung Biologics is escalating toward a general strike. The Samsung Biologics Win-Win Labor Union held a large-scale rally to vow a fight at the Incheon Songdo headquarters on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results